CRL – Charles River Laboratories International, Inc.
Float Short %
4.49
Margin Of Safety %
25
Put/Call OI Ratio
0.56
EPS Next Q Diff
-0.74
EPS Last/This Y
9.97
EPS This/Next Y
0.55
Price
161.74
Target Price
167.5
Analyst Recom
2.58
Performance Q
19.35
Relative Volume
1.43
Beta
1.48
Ticker: CRL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | CRL | 176.95 | 0.71 | 0.70 | 11994 |
| 2025-07-28 | CRL | 179.03 | 0.71 | 0.51 | 12298 |
| 2025-07-29 | CRL | 178.44 | 0.73 | 0.44 | 12270 |
| 2025-07-30 | CRL | 176.31 | 0.72 | 1.85 | 12279 |
| 2025-07-31 | CRL | 169.59 | 0.72 | 5.22 | 12315 |
| 2025-08-01 | CRL | 166.81 | 0.74 | 0.05 | 12426 |
| 2025-08-04 | CRL | 167.85 | 0.72 | 0.59 | 12629 |
| 2025-08-05 | CRL | 167.49 | 0.57 | 0.94 | 14713 |
| 2025-08-06 | CRL | 150.36 | 0.59 | 0.30 | 17669 |
| 2025-08-07 | CRL | 149.78 | 0.56 | 0.11 | 18574 |
| 2025-08-08 | CRL | 148.76 | 0.53 | 0.03 | 18910 |
| 2025-08-11 | CRL | 148.91 | 0.52 | 0.04 | 18970 |
| 2025-08-12 | CRL | 152.75 | 0.48 | 0.06 | 19966 |
| 2025-08-13 | CRL | 155 | 0.47 | 0.02 | 20680 |
| 2025-08-14 | CRL | 155.77 | 0.46 | 0.02 | 20967 |
| 2025-08-15 | CRL | 156.56 | 0.46 | 0.42 | 20827 |
| 2025-08-18 | CRL | 156.99 | 0.54 | 0.20 | 6888 |
| 2025-08-19 | CRL | 158.49 | 0.54 | 1.03 | 7155 |
| 2025-08-20 | CRL | 159.6 | 0.55 | 0.24 | 7090 |
| 2025-08-21 | CRL | 154.53 | 0.56 | 0.04 | 7023 |
| 2025-08-22 | CRL | 161.74 | 0.56 | 0.02 | 7036 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | CRL | 176.93 | -11.2 | 454.9 | 9.63 |
| 2025-07-28 | CRL | 179.36 | -11.2 | 461.7 | 9.63 |
| 2025-07-29 | CRL | 178.45 | -11.2 | 454.0 | 9.63 |
| 2025-07-30 | CRL | 176.19 | -11.2 | 449.5 | 9.63 |
| 2025-07-31 | CRL | 169.64 | -10.6 | 438.3 | 9.65 |
| 2025-08-01 | CRL | 166.91 | -10.6 | 448.0 | 9.65 |
| 2025-08-04 | CRL | 167.92 | -10.6 | 458.1 | 9.65 |
| 2025-08-05 | CRL | 167.49 | -10.6 | 454.2 | 9.65 |
| 2025-08-06 | CRL | 150.36 | -10.6 | 409.1 | 9.65 |
| 2025-08-07 | CRL | 149.78 | -10.6 | 453.8 | 9.65 |
| 2025-08-08 | CRL | 148.74 | -8.6 | 503.3 | 10.14 |
| 2025-08-11 | CRL | 148.88 | -8.6 | 510.7 | 10.14 |
| 2025-08-12 | CRL | 152.77 | -9.1 | 521.8 | 10.17 |
| 2025-08-13 | CRL | 155.00 | -9.2 | 516.9 | 10.17 |
| 2025-08-14 | CRL | 155.72 | -9.2 | 512.4 | 10.17 |
| 2025-08-15 | CRL | 156.70 | -9.2 | 512.9 | 10.17 |
| 2025-08-18 | CRL | 156.97 | -9.2 | 511.1 | 10.17 |
| 2025-08-19 | CRL | 158.48 | -9.2 | 514.6 | 10.17 |
| 2025-08-20 | CRL | 159.58 | -9.2 | 513.4 | 10.17 |
| 2025-08-21 | CRL | 154.60 | -9.2 | 496.0 | 10.17 |
| 2025-08-22 | CRL | 161.74 | -9.2 | 531.4 | 10.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | CRL | 0.44 | 0.32 | 4.77 |
| 2025-07-28 | CRL | 0.44 | -0.56 | 4.77 |
| 2025-07-29 | CRL | 0.44 | -0.56 | 4.77 |
| 2025-07-30 | CRL | 0.44 | -0.56 | 4.77 |
| 2025-07-31 | CRL | 0.44 | -0.56 | 4.77 |
| 2025-08-01 | CRL | 0.44 | -0.56 | 4.77 |
| 2025-08-04 | CRL | 0.44 | -0.46 | 4.77 |
| 2025-08-05 | CRL | 0.44 | -0.46 | 4.77 |
| 2025-08-06 | CRL | 0.44 | -0.46 | 4.77 |
| 2025-08-07 | CRL | 0.44 | -0.46 | 4.77 |
| 2025-08-08 | CRL | 0.37 | -0.46 | 4.77 |
| 2025-08-11 | CRL | 0.37 | -0.16 | 4.76 |
| 2025-08-12 | CRL | 0.35 | -0.16 | 4.50 |
| 2025-08-13 | CRL | 0.37 | -0.16 | 4.49 |
| 2025-08-14 | CRL | 0.37 | -0.16 | 4.49 |
| 2025-08-15 | CRL | 0.37 | -0.16 | 4.49 |
| 2025-08-18 | CRL | 0.37 | -3.47 | 4.49 |
| 2025-08-19 | CRL | 0.37 | -3.47 | 4.49 |
| 2025-08-20 | CRL | 0.37 | -3.47 | 4.49 |
| 2025-08-21 | CRL | 0.22 | -3.47 | 4.49 |
| 2025-08-22 | CRL | -0.36 | -3.47 | 4.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.12
Avg. EPS Est. Current Quarter
2.35
Avg. EPS Est. Next Quarter
2.38
Insider Transactions
-0.36
Institutional Transactions
-3.47
Beta
1.48
Average Sales Estimate Current Quarter
982
Average Sales Estimate Next Quarter
980
Fair Value
202.77
Quality Score
48
Growth Score
56
Sentiment Score
44
Actual DrawDown %
64.9
Max Drawdown 5-Year %
-78.2
Target Price
167.5
P/E
Forward P/E
15.03
PEG
P/S
1.98
P/B
2.37
P/Free Cash Flow
13.77
EPS
-1.32
Average EPS Est. Cur. Y
10.17
EPS Next Y. (Est.)
10.72
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1.72
Relative Volume
1.43
Return on Equity vs Sector %
-26.8
Return on Equity vs Industry %
-12.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.54
EBIT Estimation
531.4
Charles River Laboratories InteSector: Healthcare
Industry: Diagnostics & Research
Employees: 18700
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
stock quote shares CRL – Charles River Laboratories International, Inc. Stock Price stock today
news today CRL – Charles River Laboratories International, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRL – Charles River Laboratories International, Inc. yahoo finance google finance
stock history CRL – Charles River Laboratories International, Inc. invest stock market
stock prices CRL premarket after hours
ticker CRL fair value insiders trading